Gain exclusive insights into Troikaa Pharmaceuticals’ journey
Ensuring the prompt availability of life-saving medicine is essential, yet conventional sterility testing methods can delay product release for weeks. Troikaa Pharmaceuticals Ltd., a global leader in pharmaceutical innovation, overcame this challenge by adopting Celsis® ATP-bioluminescence, an advanced Rapid Microbial Method (RMM) that reduces sterility testing time to 6-7 days.
In this case study, you will learn how they:
- Evaluated and validated multiple rapid sterility testing methods
- Chose Celsis to meet regulatory compliance and accelerate timelines
- Improved operational efficiency without compromising safety or quality
Who would benefit from the information in this case study, and how?
Pharmaceutical manufacturers
Model the success of an industry leader and learn how they modernized their QC process, reduced warehouse costs, and maintained regulatory compliance with advanced sterility testing.
Microbiology professionals
Gain actionable insights from Troikaa’s evaluation of innovative technologies led by an experienced microbiology team.
Decision-makers
Understand how adopting Celsis ATP-bioluminescence can transform your lab's operations and enable faster, safer product release.
During our evaluation of rapid sterility systems, we found that Charles River’s Celsis system outperformed other commercially available options for RMM. The system aligns closely with compendial expectations and —being a growth-based method— provides greater assurance of product safety. The Charles River team was instrumental in supporting us throughout every stage of qualification and implementation. Their collaborative approach ensured a smooth and effective transition to the new system.”
Vinod Patel, Sr Vice President, Troikaa Pharmaceuticals Ltd.